Paracetamol is not classified as an anti-inflammatory drug. Pharmacologists group it separately from nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen because it does very little to reduce the redness, swelling, and heat that define peripheral inflammation. Yet the full story is more interesting than a flat “no.” Paracetamol does interact with some of the same enzyme pathways that NSAIDs target, and recent research suggests it may suppress inflammation in the brain while leaving inflammation elsewhere in the body largely untouched.
Why Paracetamol Falls Outside the NSAID Category
NSAIDs work by blocking cyclooxygenase enzymes, commonly called COX-1 and COX-2. These enzymes help produce prostaglandins, which are chemicals your body releases at sites of injury or infection. Prostaglandins drive swelling, pain sensitivity, and fever. By blocking the enzymes, NSAIDs reduce all three at once, including the visible inflammation in a swollen joint or a sprained ankle.
Paracetamol also interacts with cyclooxygenase enzymes, but in lab tests it shows low potency against both COX-1 and COX-2.1PubMed Central. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action One leading explanation is that paracetamol can only inhibit these enzymes in tissues where peroxide levels are low. Inflamed tissue is flooded with peroxides from immune cells, which essentially overrides paracetamol’s ability to shut down prostaglandin production there.2PubMed. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? That is why a standard dose of paracetamol can bring down a fever but will not reduce the swelling in an inflamed knee the way ibuprofen would.
How Paracetamol Actually Relieves Pain
If paracetamol barely touches the prostaglandin system at inflamed sites, how does it ease a headache or a sore throat? Researchers have been wrestling with this question for decades, and the honest answer is that the mechanism is still not fully nailed down. Several pathways appear to contribute, but a 2025 study has put a spotlight on one in particular.
After you swallow paracetamol, your body converts some of it into a metabolite called AM404. This metabolite was long thought to act mainly in the brain, interacting with cannabinoid receptors and a heat-sensing channel called TRPV1. But the 2025 study found that AM404 is also produced directly by pain-sensing nerve cells outside the brain. There, it blocks specific sodium channels (Nav1.7 and Nav1.8) that these neurons need to fire pain signals. In experiments on rats, this peripheral sodium-channel blockade was enough to reduce pain responses in both normal and inflamed tissue.3PubMed Central. The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels The effect was specific to AM404 and did not occur with other breakdown products of paracetamol.
Separately, reactive metabolites of paracetamol (including NAPQI, the same compound responsible for liver toxicity at high doses) have been shown to activate and sensitize the TRPV1 channel in spinal sensory neurons. In one study, NAPQI applied to the skin of human volunteers triggered a brief burning sensation and localized neurogenic inflammation, confirming that the metabolite reaches pain-related pathways.4PubMed Central. Reactive metabolites of acetaminophen activate and sensitize the capsaicin receptor TRPV1 How this TRPV1 activation contributes to overall pain relief rather than pain itself is still being worked out, but the involvement of multiple distinct pathways helps explain why pinning down a single mechanism has been so difficult.
The Brain Exception
The peroxide story has an important flip side. While inflamed peripheral tissues have high peroxide concentrations that block paracetamol’s effect on COX enzymes, the brain operates at much lower peroxide levels. That creates a window where paracetamol can reduce prostaglandin production in the central nervous system even while prostaglandin levels in the rest of the body stay largely unchanged.
One study comparing brain macrophages (microglia) to peripheral macrophages found that paracetamol reduced prostaglandin E2 production in microglia at concentrations roughly a thousand times lower than what was needed to achieve the same effect in peripheral immune cells.5PubMed. Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase The researchers proposed that this selectivity makes paracetamol a useful tool for treating brain inflammation without disrupting prostaglandin signaling elsewhere. That distinction matters because prostaglandins in the gut, for instance, help protect the stomach lining, and knocking them out systemically is what gives NSAIDs their well-known gastrointestinal side effects.
So paracetamol does have anti-inflammatory activity, but it is concentrated in the brain rather than at the sites where you would normally see swelling and redness. This central anti-inflammatory action is closely tied to its ability to reduce fever, which is driven by prostaglandins produced in the brain’s temperature-regulation center.
How It Reduces Fever
Fever is the result you’re most likely to associate with paracetamol, and it is the clearest clinical expression of its central COX inhibition. When your immune system detects an infection, signaling molecules prompt the brain to ramp up prostaglandin production in the hypothalamus, the region that sets your body’s thermostat. Paracetamol inhibits cyclooxygenase activity in that region and resets the thermostat back toward normal.6PubMed. Paracetamol in fever in critically ill patients-an update Animal data also point to a COX-1 variant enzyme as a mediator of both paracetamol’s pain-relieving and fever-lowering effects.1PubMed Central. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action
NSAIDs also reduce fever through central COX inhibition, so on a fever chart the two drug classes can look similar. The practical difference is everything else that goes along with NSAID use: reduced peripheral inflammation, but also reduced protection for the stomach and altered platelet behavior. If you only need to bring down a temperature and ease mild discomfort, paracetamol gets you there without those extras.
Head-to-Head With NSAIDs for Inflammatory Conditions
The distinction between paracetamol and NSAIDs becomes starkest when the clinical problem is driven by inflammation. In rheumatoid arthritis, a Cochrane review compared the two classes and found that patients and investigators alike tended to prefer NSAIDs. In the largest included trial, about 37% of patients preferred ibuprofen compared with 13% who preferred paracetamol. In another trial, investigators judged diclofenac superior based on joint tenderness, grip strength, and joint circumference. The evidence base was too weak for firm conclusions, but the pattern was consistent: when inflammation is the core problem, paracetamol underperforms.7Cochrane Database of Systematic Reviews. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis
In osteoarthritis, where inflammation is present but less dominant, paracetamol has been widely recommended as a first-line option for years. Yet the clinical evidence supporting this recommendation is thin. A Cochrane review found that paracetamol provided only minimal improvements in both pain and physical function for people with hip or knee osteoarthritis.8Cochrane Database of Systematic Reviews. Paracetamol for treating people with hip or knee osteoarthritis Another analysis put numbers to it: the improvement over placebo was roughly 3% for both pain and physical function.9BMJ Evidence-Based Medicine. Paracetamol as first line for treatment of knee and hip osteoarthritis For context, a difference that small falls well below what patients can actually feel. Paracetamol is still commonly prescribed for osteoarthritis, partly because of its favorable safety profile, but the idea that it meaningfully helps with the condition has been eroding for some time.10PubMed Central. Safety of Paracetamol in Osteoarthritis: What Does the Literature Say?
In acute pain scenarios like wisdom tooth extraction, the gap is clearer still. A Cochrane review of post-surgical dental pain found that 400 mg ibuprofen was superior to 1000 mg paracetamol for pain relief, with patients on ibuprofen roughly 50% more likely to achieve at least half their pain gone by six hours and similarly less likely to need rescue medication.11PubMed Central. Ibuprofen and/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth Dental extraction pain involves significant local inflammation, which again plays to the NSAID’s strengths.
Combining Paracetamol With an NSAID
Because paracetamol and NSAIDs work through different mechanisms, combining them can produce better pain relief than either one alone. An expert panel reviewing the evidence for pediatric use described the two drugs’ mechanisms as complementary, noting synergy between their effects.12PubMed Central. Paracetamol and ibuprofen combination for the management of acute mild-to-moderate pain in children: expert consensus using the Nominal Group Technique (NGT) In a dose-ranging trial after oral surgery, even a quarter-dose combination of paracetamol and ibuprofen outperformed placebo, and the effect was consistent across all dose levels tested.13PubMed. Combination paracetamol and ibuprofen for pain relief after oral surgery: a dose ranging study Multiple studies support the idea that combining the two extends the duration of pain relief as well.14Biomedicine & Pharmacotherapy. Pharmacological bases of combining nonsteroidal antiinflammatory drugs and paracetamol
In practice, this combination is one of the most common over-the-counter pain strategies and is widely regarded as safer than simply increasing the dose of either drug. The logic is straightforward: paracetamol contributes central pain modulation and sodium-channel effects, while the NSAID handles the peripheral inflammatory component. Together, they cover more of the pain cascade than either manages alone.
Safety Differences That Matter
Much of paracetamol’s clinical niche comes not from being a powerful painkiller but from the side effects it avoids. NSAIDs suppress prostaglandins throughout the body, which is why they can irritate the stomach lining, increase the risk of GI bleeding, and interfere with blood clotting. Paracetamol, by contrast, had no effect on bleeding time or platelet aggregation in a comparative study with aspirin.15PubMed. A comparative study of the effects of aspirin and paracetamol (acetaminophen) on platelet aggregation and bleeding time That makes it the go-to choice for people on blood thinners, those with a history of stomach ulcers, or patients heading into surgery where bleeding risk matters.
However, the assumption that paracetamol is entirely gentle on the cardiovascular system has been challenged. Recent evidence indicates that paracetamol, like most NSAIDs, can raise blood pressure, and certain formulations containing sodium may increase cardiovascular risk. Paracetamol also appears to influence coagulation through effects on vitamin K metabolism, a pathway distinct from the platelet effects of NSAIDs.16PubMed. Acetaminophen, Nonsteroidal Anti-Inflammatory Drugs, and Hypertension These findings do not put paracetamol on the same risk level as NSAIDs for most people, but they do erode the idea that it is cardiovascularly inert.
A concern that gets less public attention than pediatric asthma fears in the early 2000s: the worry that paracetamol use in children might trigger wheezing or asthma exacerbations. A meta-analysis of five randomized controlled trials covering over 85,000 children found no difference in asthma or wheezing outcomes between children treated with paracetamol and those given ibuprofen.17PubMed Central. Risk of wheezing and asthma exacerbation in children treated with paracetamol versus ibuprofen: a systematic review and meta-analysis of randomised controlled trials That worry appears to have been a false alarm from earlier observational data that could not account for confounding factors.
Liver Toxicity at High Doses
The most serious risk unique to paracetamol is liver damage from overdose. At normal doses, about 90% of the drug is processed through safe metabolic pathways and excreted by the kidneys. A small fraction gets converted by liver enzymes into a reactive metabolite called NAPQI, which is normally neutralized by a molecule called glutathione. In overdose, however, the safe pathways become saturated. Far more NAPQI is produced, glutathione stores are overwhelmed, and the reactive metabolite begins binding to mitochondrial proteins and destroying liver cells.18PubMed Central. Liver injury induced by paracetamol and challenges associated with intentional and unintentional use
The damage is dose-dependent: the more paracetamol taken above the safe ceiling, the more prolonged the depletion of glutathione and the more severe the liver injury.19PubMed Central. Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology This toxicity pathway has been confirmed in both animal models and human cases, and it closely involves mitochondrial dysfunction, oxidative stress, and ultimately cell death.20Biochemistry and Biophysics Reports. Unveiling the molecular basis of paracetamol-induced hepatotoxicity: Interaction of N-acetyl-p-benzoquinone imine with mitochondrial succinate dehydrogenase Paracetamol overdose remains the leading cause of acute liver failure in many Western countries, which is worth keeping in mind given how casually the drug is used and how many combination products (cold medicines, sleep aids, prescription painkillers) contain it without the name appearing prominently on the label.
Emerging Research on Neuroinflammation
While paracetamol clearly falls short of NSAIDs for treating peripheral inflammation, a growing line of research suggests it has underappreciated effects on inflammation within the brain. A 2025 paper testing a novel paracetamol derivative against experimentally induced neuroinflammation noted that there is increasing evidence paracetamol itself has anti-neuroinflammatory properties.21PubMed. A novel paracetamol derivative alleviates lipopolysaccharide-induced neuroinflammation This dovetails with the earlier finding that paracetamol suppresses prostaglandin production in brain macrophages at far lower concentrations than it needs to affect peripheral immune cells.5PubMed. Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase
This is early-stage science, and nobody is recommending paracetamol as a treatment for neuroinflammatory diseases. But it opens an intriguing possibility: the drug millions of people take for headaches might be doing more in the brain than just interrupting pain signals. Whether that central anti-inflammatory activity has any meaningful long-term consequences, beneficial or harmful, remains an open question that researchers are only beginning to explore with purpose-designed studies and modified compounds. For now, the practical takeaway stays the same. Paracetamol is a pain reliever and a fever reducer. It is not an anti-inflammatory in any clinically meaningful peripheral sense, but the boundary between those categories is less clean than the labels on the pharmacy shelf suggest.